Montanide^TM Gel01 ST Adjuvant Enhances PRRS Modified Live Vaccine Efficacy by Regulating Porcine Humoral and Cellular Immune Responses

Xiangdong Li, Amy Galliher-Beckley, Jerome C. Nietfeld, Kay S. Faaberg, Jishu Shi

Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, USA.
Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, USA.
Virus and Prion Research Unit, National Animal Disease Center, United States Department of Agriculture, Ames, USA.

DOI: 10.4236/wjv.2013.31001                

Abstract

Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease caused by the PRRS virus. The Montanide^TM class of flexible polymeric adjuvants has recently been shown to enhance protective immunity against PRRSV infection in piglets when used in combination with PRRS modified live vaccines (MLV). In this study, we explored the efficacy and immunological mechanisms of protection of Montanide^TM Gel01 ST (Gel01) adjuvanted modified live PRRSV vaccine in pigs challenged with two genetically distinct strains of PRRSV. Gel01-MLV reduced lymph node pathology scores in pigs challenged with VR-2332 (parental strain of MLV vaccine) but not that in pigs challenged with MN184A (heterologous strain), when compared to that in pigs vaccinated with un-adjuvanted MLV. Pigs vaccinated with Gel01-MLV had higher levels of PRRS-specific antibodies, as measured by IDEXX ELISA and virus neutralizing antibodies, after vaccination and VR-2332 challenge. In addition, pigs vaccinated with Gel01-MLV had decreased levels of IFN-γ, IL-10, and T-regulatory lymphocytes in the blood as compared to that in pigs vaccinated with MLV alone. Interestingly, we found that addition of Gel01 did not change the profile of other T lymphocyte populations after PRRSV challenge. These results demonstrate that the MLV adjuvanted with Gel01 provides enhanced protection against homologous PRRSV infection, possibly by regulating the production of PRRSV-specific antibodies and cytokines involved in the development of T-regulatory cells. Thus, Gel01 ST is a promising adjuvant that can be formulated with PRRSV MLV vaccines to reduce disease severity and tissue damage caused by PRRSV infection in pigs.

Keywords

PRRSV; MontanideTM Gel01 ST; IFN-γ; Adjuvant; IL-10; Immune Response; Vaccine

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. J. Chand, B. R. Trible and R. R. Rowland, “Pathogenesis of Porcine Reproductive and Respiratory Syndrome Virus,” Current Opinion Virology, Vol. 2, No. 3, pp. 256-263. doi:10.1016/j.coviro.2012.02.002
[2]	United States Department of Agriculture, “PRRS Seroprevalence on U.S. Swine Operations,” 2009. http://www.aphis.usda.gov/animal_health/nahms/swine/downloads/swine2006/Swine2006_is_PRRS.pdf
[3]	T. G. Kimman, L. A. Cornelissen, R. J. Moormann, J. Rebel and N. S. Zurmieden, “Challenges for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccinology,” Vaccine, Vol. 27, No. 28, 2009, pp. 3704-3718.
[4]	W. Charerntantanakul, R. Platt, W. Johnson, M. Roof, E. Vaughn and J. A. Roth, “Immune Responses and Protection by Vaccine and Various Vaccine Adjuvant Candidates to Virulent PRRSV,” Veterinary Immunology and Immunopathology, Vol. 109, No. 1-2, 2006, pp. 99-115. doi:10.1016/j.vetimm.2005.07.026
[5]	R. Thanawongnuwech and S. Suradhat, “Taming PRRSV: Revisiting the Control Strategies and Vaccine Design,” Virus Research, Vol. 154, No. 1-2, 2010, pp. 133-140. doi:10.1016/j.virusres.2010.09.003
[6]	Y. W. Huang and X. J. Meng, “Novel Strategies and Approaches to Develop the Next Generation of Vaccines against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV),” Virus Research, Vol. 154, No. 1-2, 2010, pp. 141-149. doi:10.1016/j.virusres.2010.07.020
[7]	B. Binjawadagi, V. Dwivedi, C. Manickam, J. B. Torrelles and G. J. Renukaradhya, “Intranasal Delivery of an Adjuvanted Modified Live Porcine Reproductive and Respiratory Syndrome Virus Vaccine Reduces ROS Production,” Viral Immunology, Vol. 24, No. 6, 2011, pp. 475-482. doi:10.1089/vim.2011.0040
[8]	S. I. Jang, H. S. Lillehoj, S. H. Lee, K. W. Lee, M. S. Park, G. R. Bauchan, E. P. Lillehoj, F. Bertrand, L. Dupuis and S. Deville, “Immunoenhancing Effects of Montanide ISA Oil-Based Adjuvants on Recombinant Coccidia Antigen Vaccination against Eimeria Acervulina Infection,” Veterinary Parasitology, Vol. 172, No. 3-4, 2010, pp. 221-4218. doi:10.1016/j.vetpar.2010.04.042
[9]	S. Dveille, J. Arous, G. Ionkoff, F. Kukushkin, T. Baybikov, V. Borisov and L. Dupius, “Load Reduction in Live PRRS Vaccines Using Oil and Polymer Adjuvants,” Procedia in Vaccinology, 2012, pp. 134-140. doi:10.1016/j.provac.2012.04.018
[10]	J. Beyer, D. Fichtner, H. Schirrmeier, U. Polster, E. Weiland and H. Wege, “Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Kinetics of Infection in Lymphatic Organs and Lung,” Journal of Veterinary Medcine, Series B, Vol. 47, No. 1, 2000, pp. 9-25.
[11]	S. Dotti, R Villa, E. Sossi, G. Guadagini, F. Salvini, M. Ferrari and M. Amadori, “Comparative Evaluation of PRRS Virus Infection in Vaccinated and Naive Pigs,” Research in Veterinary Science, Vol. 90, No. 2, 2011, pp. 218-225. doi:10.1016/j.rvsc.2010.06.011
[12]	W. Charerntantanakul, R. Platt and J. A. Roth, “Effects of Porcine Reproductive and Respiratory Syndrome Virus-Infected Antigen-Presenting Cells on T Cell Activation and Antiviral Cytokine Production,” Viral immunology, Vol. 19, No. 4, 2006, pp. 646-661. doi:10.1089/vim.2006.19.646
[13]	B. Pulendran and R. Ahmed, “Immunological Mechanisms of Vaccination,” Nature Immunology, Vol. 6, No. 12, 2011, pp. 509-517.
[14]	E. Mateu and I. Diaz, “The Challenge of PRRS Immunology,” Veterinary Journal, Vol. 177, No. 3, 2008, pp. 345-351. doi:10.1016/j.tvjl.2007.05.022
[15]	G. J. Renukaradhya, V. Dwivedi , C. Manickam , B. Binjawadagi and D. Benfield , “Mucosal Vaccines to Prevent Porcine Reproductive and Respiratory Syndrome: A New Perspective,” Animal Health Research Review, Vol. 13, No. 1, 2012, pp. 21-37 doi:10.1017/S1466252312000023
[16]	C. J. Wei, J. C. boyington, P. M. Mctamney, W. P. Kong, M. B. Pearce, L. Xu, H. Andesen, S. Rao, T. M. Tumpey, Z. Y. Yang and G. J. Nabel, “Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination,” Science, Vol. 329, No. 5995, 2010, pp. 1060-1064. doi:10.1126/science.1192517
[17]	Z. Xiao, L. Batista, S. Dee, P. Halbur and M. P. Murtaugh, “The Level of Virus-Specific T-Cell and Macrophage Recruitment in Porcine Reproductive and Respiratory Syndrome Virus Infection in Pigs Is Independent of Virus Load,” Journal of Virology, Vol. 78, No. 11, 2004, pp. 5923-5933
[18]	S. suradhat and R. Thanawongnuwech, “Upregulation of Interleukin-10 Gene Expression in the Leukocytes of Pigs Infected with Porcine Reproductive and Respiratory Syndrome Virus,” Journal of General Virology, Vol. 84, No. 10, 2003, pp. 2755-2760. doi: 10.1099/vir.0.19230-0